Barrington raised the firm’s price target range on Paysign (PAYS) to $8-$9 from a prior range of $6-$7 and keeps an Outperform rating on the shares. The firm cites the “strong outlook” for Paysign’s Patient Affordability segment for the pharmaceutical industry for its target hike.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- Strategic Positioning and Growth Potential: PaySign’s Role in Pharmaceutical Patient Affordability
- Paysign price target raised to $9 from $7 at Lake Street
- Paysign management to meet with Lake Street
- DA Davidson research director holds a bison roundup conference call
- 3 Best Stocks to Buy Now, 6/16/2025, According to Top Analysts